About Us

Kardigan is on a mission to develop multiple targeted cardiovascular treatments in parallel that bring people with cardiovascular diseases closer to the cures they deserve.

We have a cutting-edge discovery and translational research platform, a pipeline of late-stage candidates, and an industry-leading team who is driven to improve the lives of patients.

We are relentless in our pursuit to create novel medicines that modify the root causes of cardiovascular disease, moving the field beyond symptom management toward functional cures.

By targeting the underlying drivers of disease with a pipeline of complementary candidates, Kardigan is building a platform that accelerates insights into core cardiovascular pathways to address multiple conditions where no treatments exist.

Purpose Inpage Callout
“To create meaningful change for patients suffering from cardiovascular diseases, we need to think differently about how we develop new drugs. At Kardigan, we are uniting real-world patient data, AI insights, and deep cardiovascular expertise to advance therapies with the potential to transform outcomes.”
Tassos Gianakakos,

Co-Founder & CEO

Kardigan has curated a diverse pipeline with three late-stage clinical programs, each designed to move beyond symptom management and to redefine treatment approaches where patients and their families need it most. Collectively, the programs create opportunities to generate new clinical insights and data that will fuel Kardigan’s ongoing R&D and discovery efforts beyond these three disease areas.

Supported by the integration of Prolaio’s AI and real-world data platform, Kardigan is enhancing its ability to derive knowledge that can inform clinical trial design and potentially reduce the time and cost to develop meaningful new medicines.